These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation. Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285 [No Abstract] [Full Text] [Related]
44. Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia. Tefferi A; Levitt R; Lasho TL; Knudson RA; Ketterling RP Eur J Haematol; 2010 Jul; 85(1):86-7. PubMed ID: 20408872 [No Abstract] [Full Text] [Related]
45. [Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection]. Andrikovics H; Szilvási A; Meggyesi N; Király V; Halm G; Lueff S; Nahajevszky S; Mikala G; Sipos A; Lovas N; Csukly Z; Mátrai Z; Tamáska J; Tordai A; Masszi T Orv Hetil; 2007 Feb; 148(5):203-10. PubMed ID: 17344140 [TBL] [Abstract][Full Text] [Related]
49. JAK2 mutations in myeloproliferative disorders. Tefferi A; Lasho TL; Gilliland G N Engl J Med; 2005 Sep; 353(13):1416-7; author reply 1416-7. PubMed ID: 16192494 [No Abstract] [Full Text] [Related]
50. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Levine RL; Pardanani A; Tefferi A; Gilliland DG Nat Rev Cancer; 2007 Sep; 7(9):673-83. PubMed ID: 17721432 [TBL] [Abstract][Full Text] [Related]
51. Targeted cancer therapy: promise and reality. Klein S; Levitzki A Adv Cancer Res; 2007; 97():295-319. PubMed ID: 17419951 [TBL] [Abstract][Full Text] [Related]
52. Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia. Winton EF; Kota V Future Oncol; 2017 Feb; 13(5):395-407. PubMed ID: 27785927 [TBL] [Abstract][Full Text] [Related]